Meal-dependent absorption of enteric-coated sodium valproate
- PMID: 6769666
- DOI: 10.1111/j.1528-1157.1980.tb04073.x
Meal-dependent absorption of enteric-coated sodium valproate
Abstract
The effect of meals on valproic acid (VPA) absorption from an enteric coated (EC) formulation was investigated. In study I, six adult normal volunteers received a single 500 mg dose of sodium valproate in randomized treatments: fasting (A), with a meal (B) or 3 hours after a meal (C). There were significant differences between treatments in the latency period (Lp) defined as the time during which measured concentrations of VPA were less than 1 microgram/ml. Lp values for treatments A, B and C were: 1.67 +/- 1.25 hr, 6.75 +/- 3.98 hr and 7.63 +/- 3.15 hr respectively. In study II, six subjects (five from study I) received in a randomized fashion a 400 mg intravenous bolus dose of VPA and a 500 mg EC VPA tablet, 3 hours after a meal. The mean Lp value was 8.1 +/- 1.6 hr and the mean bioavailability was 100%. Clearance, volume of distribution and half-life values obtained after intravenous dosing were comparable to literature values. These results indicate that food intake delays but does not decrease the extent of absorption of VPA from an enteric coated formulation.
Similar articles
-
A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016. Clin Ther. 2009. PMID: 19843490 Clinical Trial.
-
Single-dose kinetics and bioavailability of sodium-hydrogen divalproate.Clin Neuropharmacol. 1985;8(2):156-64. doi: 10.1097/00002826-198506000-00005. Clin Neuropharmacol. 1985. PMID: 3924399 Clinical Trial.
-
Effect of food on the serum concentration profile of enteric-coated valproic acid.Neurology. 1988 Aug;38(8):1319-22. doi: 10.1212/wnl.38.8.1319. Neurology. 1988. PMID: 3135514
-
Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.Ann Pharmacother. 2006 Apr;40(4):619-25. doi: 10.1345/aph.1G617. Epub 2006 Mar 28. Ann Pharmacother. 2006. PMID: 16569797 Clinical Trial.
-
Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.Isr J Med Sci. 1984 Jan;20(1):46-9. Isr J Med Sci. 1984. PMID: 6421770
Cited by
-
Diurnal variations in steady-state plasma concentrations of valproic acid in epileptic patients.Clin Pharmacokinet. 1982 Nov-Dec;7(6):544-52. doi: 10.2165/00003088-198207060-00004. Clin Pharmacokinet. 1982. PMID: 6819106
-
Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine.CNS Drugs. 2017 May;31(5):389-403. doi: 10.1007/s40263-017-0430-3. CNS Drugs. 2017. PMID: 28405886 Review.
-
Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience.CNS Drugs. 2002;16(10):695-714. doi: 10.2165/00023210-200216100-00004. CNS Drugs. 2002. PMID: 12269862 Review.
-
Clinical pharmacokinetics of valproic acid--1988.Clin Pharmacokinet. 1988 Dec;15(6):367-89. doi: 10.2165/00003088-198815060-00002. Clin Pharmacokinet. 1988. PMID: 3149565 Review.
-
No effect of food intake on clobazam absorption.Br J Clin Pharmacol. 1983 Dec;16(6):728-30. doi: 10.1111/j.1365-2125.1983.tb02251.x. Br J Clin Pharmacol. 1983. PMID: 6661360 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources